(Q46482078)

22 December 2017

title

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis (English)

1 reference

22 December 2017

1 reference

1 reference

1 reference

Richard E Chaisson

12

1 reference

22 December 2017

William J Burman

1

1 reference

22 December 2017

Stefan Goldberg

2

1 reference

22 December 2017

John L Johnson

3

1 reference

22 December 2017

Grace Muzanye

4

1 reference

22 December 2017

Melissa Engle

5

1 reference

22 December 2017

Ann W Mosher

6

1 reference

22 December 2017

Shurjeel Choudhri

7

1 reference

22 December 2017

Charles L Daley

8

1 reference

22 December 2017

Sonal S Munsiff

9

1 reference

22 December 2017

Zhen Zhao

10

1 reference

22 December 2017

Andrew Vernon

11

1 reference

22 December 2017

language of work or name

English

0 references

publication date

4 May 2006

1 reference

22 December 2017

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

22 December 2017

volume

174

1 reference

22 December 2017

page(s)

331-338

1 reference

22 December 2017

issue

3

1 reference

22 December 2017

Activity of moxifloxacin against mycobacteria

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clini

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Reassuring safety profile of moxifloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Outpatient gatifloxacin therapy and dysglycemia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

A nested case-control study on treatment-related risk factors for early relapse of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Hong Kong Chest Service/British Medical Research Council

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200603-360OC

10.1164/RCCM.200603-360OC

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

PubMed ID

16675781

1 reference

22 December 2017